Austin Smith
Senior Director, Process Chemistry CMC Eli Lilly & Co.
Seminars
- Detailing control strategies for controlling drug-linker impurities in ADCs, as outlined by the IQ Working Group
- Discussing phase-appropriate strategy for controlling ADC drug-linker impurities
- Understanding considerations for conjugatable versus non-conjugatable impurities
Bringing this brand-new seminar day to a close, don’t miss the final speaker panel discussion to ask any unanswered questions from the scientific presentations. With your fellow process, analytical, and CMC experts, break down the challenges and understand the unique considerations in ADC CQAs from a small and large molecule perspective
As we welcome the rise of ADCs with new payload and targeting moieties, ensuring your candidates meet CQA standards is paramount to understand and control all the factors influencing ADC efficacy and safety profiles.
Join this new seminar day to identify, understand and meet the breadth of ADC CQAs across DAR, charge variance, impurities, novel payload characterization and beyond to maximize ADC quality and process control
Download the Full Event Guide for full details
